Mendel Capital Management LLC bought a new stake in Amgen Inc. (NASDAQ: AMGN – Get Rating) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,736 shares of the medical research company stock, valued at approximately $ 840,000. Amgen comprises about 0.8% of Mendel Capital Management LLC’s holdings, making its stock its 25th largest position.
A number of other hedge funds and other institutional investors have also recently modified their holdings of AMGN. OLD Mission Capital LLC purchased a new stake in Amgen in the 3rd quarter worth approximately $ 239,000. Morgan Stanley boosted its position in Amgen by 0.8% in the 2nd quarter. Morgan Stanley now owns 10,040,932 shares of the medical research company stock worth $ 2,447,476,000 after purchasing an additional 80,922 shares in the last quarter. Keudell Morrison Wealth Management boosted its position in Amgen by 12.5% in the 3rd quarter. Keudell Morrison Wealth Management now owns 3,085 shares of the medical research company stock worth $ 656,000 after purchasing an additional 343 shares in the last quarter. Gotham Asset Management LLC purchased a new stake in Amgen in the 3rd quarter worth approximately $ 460,000. Finally, Cubist Systematic Strategies LLC boosted its position in Amgen by 6.3% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 12,302 shares of the medical research company stock worth $ 2,616,000 after purchasing an additional 728 shares in the last quarter. Hedge funds and other institutional investors own 79.01% of the company stock.
NASDAQ AMGN opened at $ 235.70 on Wednesday. The stock has a market cap of $ 125.91 billion, a PE ratio of 23.20, a P / E / G ratio of 2.06 and a beta of 0.57. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. Amgen Inc. has a twelve month low of $ 198.64 and a twelve month high of $ 258.45. The stock has a fifty day simple moving average of $ 246.50 and a 200-day simple moving average of $ 233.48.
Amgen (NASDAQ: AMGN – Get Rating) last announced its earnings results on Wednesday, April 27th. The medical research company reported $ 4.25 EPS for the quarter, beating analysts’ consensus estimates of $ 4.22 by $ 0.03. Amgen had a return on equity of 165.95% and a net margin of 21.75%. The company had revenue of $ 6.24 billion during the quarter, compared to analysts’ expectations of $ 6.09 billion. During the same period last year, the business posted $ 3.70 EPS. Research analysts predict that Amgen Inc. will post 17.44 EPS for the current year.
In other Amgen news, Director R Sanders Williams sold 600 shares of Amgen stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $ 250.00, for a total value of $ 150,000.00. Following the transaction, the director now directly owns 5,501 shares in the company, valued at approximately $ 1,375,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jonathan P. Graham sold 13,500 shares of Amgen stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $ 241.81, for a total value of $ 3,264,435.00. Following the completion of the transaction, the executive vice president now owns 37,333 shares in the company, valued at $ 9,027,492.73. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by company insiders.
AMGN has been the subject of several research analyst reports. Barclays upped their target price on Amgen from $ 233.00 to $ 236.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 12th. TheStreet downgraded Amgen from a “b +” rating to a “c +” rating in a research note on Wednesday, April 27th. Piper Sandler upped their target price on Amgen from $ 255.00 to $ 260.00 in a research note on Thursday, April 28th. SVB Leerink started coverage on Amgen in a research note on Monday, May 23rd. They set a “market perform” rating and a $ 256.00 target price for the company. Finally, BMO Capital Markets reduced their price objective on Amgen from $ 263.00 to $ 243.00 in a research note on Thursday, April 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $ 242.57.
Amgen Company Profile: (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology / hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due to a low white blood cell count in cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ: AMGN – Get Rating).
Receive News & Ratings for Amgen Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.